Test Price
2,800 AED✅ Home Collection Available
TBP Gene Spinocerebellar Ataxia Type 17 (SCA17), Autosomal Dominant, Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited next‑generation sequencing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM – 11 PM).
Clinical Guidance: Post‑test tele‑consultation with a specialist genetic counsellor.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The TBP Gene Genetic Test detects pathogenic variants in the TATA‑box binding protein gene causing Spinocerebellar Ataxia Type 17 (SCA17), an autosomal dominant neurodegenerative disorder. This next‑generation sequencing analysis provides definitive molecular diagnosis for ataxia and related neurological symptoms, enabling precise genetic counselling and family planning.
| Feature | Our Test (NGS Full‑Gene Sequencing) | Closest Alternative (Targeted Mutation Panel) |
|---|---|---|
| Precision | >99.9% analytical sensitivity for single nucleotide variants & small indels | Only known hot‑spot mutations; miss rare variants |
| Method | Next‑Generation Sequencing (Illumina® platform, 250× mean depth) | Sanger sequencing or MLPA; limited coverage |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Clinical Utility | Complete TBP gene coverage – diagnostic, predictive & prenatal | Confirmation of known familial mutation only |
Physician Insight & Safety Protocols
Note from Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403):
"As a clinical geneticist, I emphasise that this test provides a definitive molecular diagnosis for SCA17. However, the result must be interpreted alongside the patient's neurological examination, family history, and imaging findings. A positive result allows early intervention with symptomatic therapies and genetic counselling; a negative result may warrant further investigation for other ataxias. I encourage you to discuss the result with your treating physician or our genetic counsellor."
Safety Advisory
Do not discontinue any prescribed medication or alter your treatment plan without first consulting your doctor. This test is for diagnostic purposes only and does not override ongoing clinical management.
Safety Exclusion Criteria
- Test not recommended during acute neurological crisis (e.g., stroke‑like episode) – stabilise patient first.
- For minors, sample collection requires legal guardian consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- If the patient experiences rapid worsening of ataxia, difficulty swallowing with choking, or loss of ambulation, seek immediate medical attention at the nearest ER.
- Do not use FTA card samples if the patient has undergone haematopoietic stem cell transplantation within 90 days – whole blood is required.
Patient FAQ & Clinical Guidance
1. What does the TBP Gene NGS test detect, and who should consider it?
The TBP Gene NGS test detects pathogenic expansions and sequence variants in the TBP gene causing Spinocerebellar Ataxia Type 17 (SCA17)—an adult‑onset neurodegenerative disorder. Ideal candidates include individuals with progressive cerebellar ataxia, dysarthria, and a positive family history, as well as asymptomatic adults with a known familial mutation seeking predictive testing.
2. How accurate is this genetic test for diagnosing SCA17?
Our NGS‑based assay achieves >99.9% diagnostic sensitivity and 100% specificity for the TBP gene, ensuring that a positive result confirms SCA17 with near‑certainty. The methodology employs full‑gene coverage with deep sequencing, validated against orthogonal methods and international reference standards (dbSNP, ClinVar).
3. How is the sample collected, and what is the turnaround time?
A certified phlebotomist collects 3–5 mL of whole blood in an EDTA tube, or you may provide a one‑drop blood spot on an FTA card via our VIP home collection service (8 AM – 11 PM). The molecular analysis requires 3 to 4 weeks; results are delivered securely with a tele‑consultation to explain the findings.
UAE Regulatory & Data Privacy Adherence
This genetic test and all associated data handling comply with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient information is encrypted, stored securely, and processed solely for diagnostic purposes. Clinical safety and consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is DHA-licensed (Facility No. 1143) and ISO 9001:2015 certified.
Clinical & Logistical Metadata
| Test Name | TBP Gene Spinocerebellar Ataxia Type 17 (SCA17), Autosomal Dominant, Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA tube) or FTA card (capillary blood spot) |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene coverage, 250× mean depth |
| ICD-10-CM Code | G11.8 (Other hereditary ataxias) |
| LOINC Code | 80862-0 (Spinocerebellar ataxia type 17 gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians